Novel gene-based therapies for disease will depend in many cases on long-term persistent transgene expression. To develop gene therapy strategies for Friedreich's ataxia (FRDA), we have examined the persistence of transgene expression in the brain in vivo provided by the entire 135 kb FXN genomic DNA locus delivered as an infectious bacterial artificial chromosome (iBAC) herpes simplex virus type 1 (HSV-1)-based vector injected in the adult mouse cerebellum. We constructed genomic DNA-reporter fusion vectors carrying a complete 135 kb FXN genomic locus with an insertion of the Escherichia coli lacZ gene at the ATG start codon (iBAC-FXN-lacZ). SHSY5Y human neuroblastoma cells transduced by iBAC-FXN-lacZ showed high efficiency of vector delivery and LacZ expression. Direct intracranial injection of iBAC-FXN-lacZ into the adult mouse cerebellum resulted in a large number of easily detectable transduced cells, with LacZ expression driven by the FXN genomic locus, which persisted for at least 75 days. Green fluorescent protein expression driven from the same vector but by the strong HSV-1 IE4/5 promoter was transient. Our data demonstrate for the first time sustained transgene expression in vivo by infectious delivery of a genomic DNA locus 4100 kb in size. Such an approach may be suitable for gene rescue strategies in neurological disease, such as FRDA.
INTRODUCTION
Although encouraging progress has been made in pharmacological interventions for neurological diseases, many treatments are palliative and most disorders remain untreatable. Therefore, to increase the number of therapeutic options, it is essential to explore new strategies such as gene therapy. Friedreich's ataxia (FRDA) is a genetic disorder, which has certain characteristics rendering it amenable to gene therapy approaches. The molecular cause of the disease has been identified as being due to mutations at a single locus, the FXN gene, which produces the protein frataxin, reduced levels of which lead to cell dysfunction and death. Gene rescue approaches need only to raise frataxin expression to above threshold levels, but must guarantee sustained expression of this supplementary amount of frataxin. This poses a technical difficulty because viral vector-mediated gene delivery frequently suffers from lack of persistence of transgene expression due to several reasons: the vector genome may be degraded and/or eliminated; cellular defense mechanisms directed at foreign genetic material (for example methylation, innate immune responses) may lead to transgene silencing; alterations in chromatin structure render the transgene unavailable for expression; transcriptional or translational downregulation may occur due to decreased availability of factors, which bind to vector-encoded elements affecting these processes.
In contrast to minimal promoters and cDNA transgene cassettes, genomic loci contain all of the sequence elements necessary for physiological regulation. Most viral vectors do not have sufficient transgene capacity to deliver a complete genomic locus 4100 kb, the exception being viral vector systems based on herpesviruses. The best developed of these is the herpes simplex virus type 1 (HSV-1) amplicon vectors, which are able to deliver up to 150 kb of exogenous DNA and provide efficient delivery into post-mitotic cells such as neurons. We have previously developed an infectious bacterial artificial chromosome (iBAC) vector to deliver and express a complete 135 kb FXN genomic locus in an HSV-1 amplicon in vitro to correct the biochemical deficit in primary fibroblasts from FRDA patients. 1 In this study, we have developed an iBAC-FXN vector, which encodes two reporter genes: one driven by a typical strong viral promoter (the HSV-1 IE4/5 promoter), and the other embedded at the translational start site of the FXN genomic locus transgene within the insert to assess the relative duration of expression from a strong viral promoter and a large genomic DNA locus.
In addition to a very large transgene capacity, HSV-1 vectors have a number of further advantages as gene therapy vectors. In infected neurons, vector genomes persist in an episomal form, reducing the risk of insertional mutagenesis. We have previously shown that therapeutic levels of transgenes can be delivered to distant sites in the brain by anterograde and retrograde axonal transport, such as to Purkinje cells in the cerebellum. 2 We also reported that delivery of HSV-1 amplicon vectors expressing an FXN cDNA construct resulted in functional improvement in a mouse model of FRDA, although the duration of the effect was transient. 3 The development of a genomic DNA FXN expression vector will overcome the short-lived duration of expression often associated with such expression cassettes driven by heterologous promoters. In earlier work, we have demonstrated that even though expression of a lacZ-reporter transgene in a HSV-1 vector diminished to undetectable levels after several months in vivo, vector genomes persisted and could be reactivated by helper virus infection. 4 Together with the fact that wild-type HSV-1 is known to persist in the central nervous system for the lifetime of infected individuals, these results indicate that HSV-1 vectors have the potential to mediate persistent long-term transgene expression if appropriate regulatory elements are present in the vector genome.
Here, as part of our aim to develop gene therapy approaches for FRDA we show robust and prolonged FXN genomic DNA expression in the brain in vivo from a 135-kb whole locus FXN transgene. This is the first demonstration of sustained expression from a large genomic DNA locus (4100 kb) delivered by infectious viral delivery and opens the way for a novel approach for gene therapy for neurological disease.
RESULTS AND DISCUSSION
We have previously described the construction of an iBAC-FXN vector containing a 135-kb entire genomic locus of the human FXN gene. 1 To further investigate the feasibility of using such viral vectors for gene therapy of FRDA, our next step was to characterize the expression kinetics in vivo of the FXN transgene in such iBAC vectors. We thus constructed the iBAC-FXN-lacZ-reporter vector plasmid ( Figure 1 ) using Rec/ET-mediated homologous recombination to insert a lacZreporter gene cassette at the start codon (ATG) of the human FXN genomic locus in exon 1 in the BAC-FXN plasmid 1 (Figure 1a ). Correctly modified clones were confirmed by pulsed-field gel electrophoresis of NruI, NotI and BsiW1-digested DNA (Figure 1b ) and insert-vector boundaries were verified by PCR analysis (Figure 1c) . Finally, BAC-FXN-lacZ was retrofitted with the HSV-1 amplicon vector pHG, carrying the HSV-1 replication origin (oriS) and the packaging signal (pac) to generate iBAC-FXN-lacZ (Figure 1d ), which was packaged into HSV-1 virions using a helper-free packaging system. 5 We next measured the vector titer of iBAC-FXN-lacZ by detection of expression of the green fluorescent protein (GFP) marker gene present in the iBAC backbone in G16-9 cells. 5 Protein extracts of the transduced G16-9 cells showed that LacZ (b-galactosidase) expression levels driven by the FXN locus in these cells are easily detectable (Figure 2a ). We then confirmed the ability of the vector to transduce neuron-like human SHSY5Y cells and express both GFP and LacZ activity ( Figure 2b ). The number of SHSY5Y cells transduced was observed to be 50-80% the titer in G16-9 cells, indicating the high efficiency of this vector in neuronal cells. The persistence of FXN locus-driven expression was next assayed by western blot analysis of mouse primary cortical neurons transduced by iBAC-FXN-lacZ. Quantification of LacZ levels normalized with respect to the neuronal marker protein bIII-tubulin revealed FXN locus-driven expression to be still at about 80% maximal levels after 10 days of culture. Overall, our data in vitro confirm transgene expression driven by the FXN genomic DNA locus within the iBAC-FXN-lacZ vector in three cell culture models following vector transduction.
To determine the expression kinetics of the FXN locus in vivo (Figure 3) , we delivered the iBAC-FXN-lacZ vector into the cerebellum of adult C57BL/6 mice by stereotaxic injection. Mice were killed at 5, 10, 30 and 75 days post-injection and sagittal cerebellar sections were analyzed by double immunofluorescence (Figure 3a ) using antibodies specific for GFP and LacZ. Both the GFP transgene driven by the HSV-1 IE4/5 promoter and the lacZ transgene under the control of the FXN locus are encoded in the same vector and, therefore, expressed in the same cell. Thus, even though absolute expression levels of these two transgenes cannot be compared (since each antibody has a different binding affinity), a comparison of their expression kinetics can be made. Semi-quantitative analysis of these immunofluorescence data was performed by pixel integration. Since we observed an initial peak of expression at 5 days, this was used as a reference point such that all values were represented as a percentage of the value obtained at 5 days. The results of two independent experiments shown in Figures 3b and c indicate that transgene expression driven by the FXN locus (LacZ) persists for at least 75 days at approximately the same levels, while that driven by the IE4/5 promoter (GFP) is transient and decreases down to 20-50% during the same period. These data provide encouraging evidence that iBAC vector-mediated transgene expression is prolonged in vivo driven by the appropriate physiological regulation mechanisms.
Since gene therapy has the potential to provide a permanent source to supplement or replace a deficient or defective protein with a 
Long-term persistence of genomic frataxin vector
A Gimenez-Cassina et al functional one, it represents a promising approach for the treatment of recessive central nervous system diseases. Gene therapy of monogenic diseases involving loss of function of an essential protein can be approached directly by the introduction of a transgene to target cells to express viable levels of the missing protein. In FRDA, mutations in the FXN gene reduce expression levels of the mitochondrial protein frataxin, resulting in dysfunction and death of certain neurons in the spinal cord, brainstem and cerebellum. We have previously demonstrated that viral vector-mediated expression of frataxin can rescue oxidative stress hypersensitivity of FRDA patient fibroblasts 1 and the neurological deficit in a mouse FRDA model. 3 Nevertheless, permanent correction of such inherited disorders in patients will require a sustained level of expression from the therapeutic transgene, a known difficulty in many viral vectors. A unique property of herpesvirus amplicon vectors is that they are capable of transporting very large transgenes such as whole genomic loci. Amplicon vectors derived from herpesvirus efficiently infect neurons and we have shown effective frataxin cDNA delivery into the brainstem with such vectors packaged with an HSV-1 helper virus. In the present study in vivo, we have now shown that following delivery of the iBAC vector into the adult mouse cerebellum, transgene expression driven by the FXN locus is persistent for at least several months, whereas viral promoter-driven expression is transient.
In order to treat the neurological aspects of FRDA, gene therapy should raise frataxin expression and/or increase the survival of affected neurons in the dorsal root ganglia, spinal cord, brainstem and cerebellum. Transgene delivery to these target tissues can be enhanced by the ability of HSV-1 vectors to perform anterograde and retrograde transport as we have previously shown. 2 
MATERIALS AND METHODS

Vector construction
An Escherichia coli lacZ-encoding cassette and flanking kanamycin resistance gene (Kan R ) was inserted by Rec/ET homologous recombination at the ATG start codon of the human FXN gene locus within the 135-kb BAC-FXN insert Long-term persistence of genomic frataxin vector A Gimenez-Cassina et al derived from clone RP11-265B8. 1 Two B50 bp recombination arms with homology to the targeted region in the FXN locus were added to the lacZ/ Kan R cassette by PCR amplification using the proof-reading Taq polymerase BioXact Long (Bioline, London, UK). The primers used for amplification were ET_FXN_lac_F: 5¢-CGCCGCAGCACCCAGCGCGGAGGGCGGAGCGGGCG GCAGACCCGGAGCAGCATGAGCGAAAAATACATCGTCACCT-3¢ and ET_ FXN_R: 5¢-GGCTGGGTGACGCCAGGAGGCCGGCTACTGCGCGGCGCCC GAGAGTCCACATTGAAGAAGGTGTTGCTGACTCATAC-3¢.
Homologous recombination was performed as previously described. 6, 7 In brief, electrocompetent bacteria containing the target BAC-FXN and the plasmid pSC101-BAD-gba Tet (Gene Bridges GmbH, Dresden, Germany), encoding all the required genes for Rec/ET homologous recombination, were electroporated with the linearized lacZ/Kan R cassette flanked by the homology arms. The obtained colonies were screened by restriction analysis and PCR as depicted in Figure 1 . The primers used for the PCR across the newly generated junctions were P1: 5¢-ACTTCCCAGCAAGACAGCAG-3¢ and P2: 5¢-GGATCGATCTCGC CATACAG-3¢ for the new junction in the 5¢-end; and P3: 5¢-ACTTTCTGGCT GGATGATGG-3¢ and P4: 5¢-CAGAGAAGGGAGTTGCAAGG-3¢ for the new junction in the 3¢-end. Retrofitting of the FXN-lacZ BAC vector to the pHG amplicon vector (containing the HSV-1 replication origin oriS and packaging signal pac) in order to generate the iBAC-FXN-lacZ vector was performed as previously described. 1, 8 
HSV-1 vector production and infection of cell lines
The iBAC-FXN-lacZ vector was packaged into HSV-1 particles using an improved HSV-1 helper virus-free system as previously described. 5 The supernatant from three 6 cm dishes was concentrated to 250 ml Dulbecco's modified Eagle medium supplemented with 10% fetal calf serum to give a stock of 7Â10 6 transducing units ml -1 (tu ml -1 ) when titered for GFP expression on a confluent G16-9 cell layer. G16-9 cells are a derivative of the human Gli-36 glioma cell line expressing the HSV-1 VP16 protein to enhance the expression from the pIE4/5-GFP promoter cassette; these cells were a kind gift from Y Saeki and EA Chiocca and were cultured in Dulbecco's modified Eagle medium supplemented with 10% (v/v) fetal calf serum 100 U ml -1 penicillin, 100 mg ml -1 streptomycin and hygromycin-B (200 mg ml -1 ). Soluble LacZ activity in G16-9 cells was measured using the o-nitrophenyl-b-D-galactopyranoside assay. 9 For transduction of SHSY5Y human neuroblastoma, confluent monolayers of differentiated cells were prepared as previously described and infected with iBAC-FXN-lacZ at an m.o.i. 
Animal protocols
Eight-week-old male C57BL/6 mice (Charles River breeding laboratories, Barcelona, Spain) were used in this study and the mice were housed in a temperature-controlled room under a 12-h light/12-h dark cycle. Briefly, mice were anesthetized with isofluorane and placed in a stereotaxic frame (Stoelting, Wood Dale, IL, USA) to inject 3 ml of the vector iBAC-FXN-lacZ (7Â10 6 transducing units ml -1 ) into the cerebellum (AP: 6.5, lateral: 2.0; V: 2.0) over 3 min using a 5-ml Hamilton syringe. Between 3 and 5 mice per group (see Quantification of immunostaining intensity) were injected in the time course (0, 5, 10, 30 and 75 days). At the end of the experiment, the skin was sutured and anesthesia was discontinued. Mice were kept in individual cages with water and food ad libitum, and observed periodically the next days.
Primary neuron culture
Cortical primary neurons were cultured as previously described. 3 In brief, 17-day-old embryos were removed from a pregnant female mouse and dissected in pre-chilled Hank's-buffered salt solution. After removal of the meninges, striatum and hippocampus, the intact cortices were cut into small pieces and then incubated in a 0.25% trypsin (Sigma, Madrid, Spain), 1 mg ml -1 DNaseI (Roche, Barcelona, Spain) solution in Hank's-buffered salt solution without calcium and magnesium for 15 min at 371C, with gentle shaking every 3-4 min. The dissociated cells were then re-suspended and plated in minimum essential medium supplemented with 0.6% glucose and 10% horse serum (Invitrogen, Barcelona, Spain). The medium was changed after 4 h to neurobasal culture medium supplemented with B-27, 2 mmol GlutaMaxI (both from Invitrogen), and a mix of penicillin and streptomycin (100 U ml -1 and 100 mg ml -1 , respectively). The cells were plated at a density of 1Â10 5 cells cm -2 onto poly-L-lysine precoated surfaces, and one-third of the medium was replaced every 3 days. To avoid glial proliferation, Ara-C (5 mM final concentration) was added 24 h after plating. Cortical neurons were transduced after 1 day in vitro at a multiplicity of infection of 5 with pHG-F-lacZ, and then allowed to express the construct up to 10 days. Primary antibodies and the dilutions used were LacZ, polyclonal, MP Biomedicals, Inc. (Eschwege, Germany), 1:10000; bIII-tubulin, in-house polyclonal antibody, 1: 2000. 10 Densitometric analysis was performed with an imaging densitometer (GS-710 model, Bio-Rad, Hercules CA, USA). The density of each LacZ band was normalized with respect to the density of the tubulin band for the same sample; this normalized LacZ expression level was expressed in arbitrary units, setting the expression levels at day 7 at 100.
Immunohistochemistry
Mice were anesthetized at 0, 5, 10, 30 and 75 days with CO 2 , decapitated and the brain was immediately removed and fixed for 24 h in 4% paraformaldehyde in 0.1 M PBS (pH 7.4). The brains were cryoprotected in 10, 20 and then 30% sucrose (24 h each) and transverse cryostat sections of cerebellum were obtained (40 mm thick) and collected free floating in PBS. For GFP and LacZ immunohistochemistry, free-floating sections were rinsed in 0.1 M PBS (pH 7.4), preincubated at room temperature in PBS with 0.3% Triton X-100 for 1 h and then for 2 h with PBS Triton X-100 containing 5% bovine serum albumin to block non-specific binding. After washing twice with PBS Triton X-100, the slices were incubated overnight at 4 1C with a mouse polyclonal antibody against GFP (1:100) and a rabbit polyclonal antibody against LacZ (1:500, MP Biomedicals Inc.). Secondary antibodies conjugated to Alexa 488 or Alexa 594 (Invitrogen, Barcelona, Spain) were used at 1:5000. Finally, sections were mounted with coverslips using Fluoromount medium and examined on an inverted microscope (Axioskop2 plus, Zeiss MicroImaging, Barcelona, Spain) coupled to a monochrome and color charged-coupled device camera. Quantification of GFP and LacZ immunoreactivity in cerebellar sections of mice injected with iBAC-FXN-lacZ vector was carried out. All images were split and the green and red channels were marked with a rectangle that covered the injection tract and the immunoreactivity. In five sections, 40 mm apart, microscopic fields were photographed at Â5 magnification in four mice from each group and analyzed with ImageJ 1.42q (NIH, Bethesda, MD, USA).
Quantification of immunostaining intensity
For data for transgene expression persistence in adult mouse cerebellum, the number of animals per group for 0, 5, 10, 30 and 75 days post-transduction in Experiment 1 (Figure 3b) were 3, 5, 3, 5 and 3 mice, respectively, and in Experiment 2 ( Figure 3c) were 3, 4, 3, 4 and 3 mice. Three glass slides per mouse (with 4-5 slices per glass slide on average) were selected based on their localization within the injected region. Slides from mice injected with saline were processed and analyzed in parallel to substract non-specific signal. The images were examined under a Zeiss Axiovert 200 fluorescence microscope. Image acquisition as well as the quantification of fluorescence intensity were performed using a charged-coupled device camera and MetaMorph v6.2r6 software (Molecular Devices, Sunnyvale, CA, USA) as previously described. 11 For these measurements, each complete set of samples was processed in parallel, and all images were taken in one single session. All images were captured fixing all detection settings (exposure time, lamp intensity, gain, binning and gamma). All fluorescence intensity data were subjected to background normalization by selecting a non-stained area in each field and subtracting its average intensity from each single-stained area intensity.
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